AbbVie (ABBV) Cash & Current Investments (2012 - 2026)

AbbVie (ABBV) has reported Cash & Current Investments for 15 consecutive years, with $9.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 81.43% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 81.43% YoY), while the FY2025 annual figure was $5.3 billion, down 5.36% from the prior year.
• Cash & Current Investments rose to $9.4 billion in Q1 2026 per ABBV's latest filing, from $5.3 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $18.1 billion in Q1 2024 and bottomed at $5.2 billion in Q1 2025.
• Historically, Cash & Current Investments has averaged $9.2 billion across 5 years, with a median of $8.8 billion in 2023.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 168.8% — and 2025, when it plunged 71.35%.
• AbbVie's Cash & Current Investments stood at $9.2 billion in 2022, then jumped by 38.87% to $12.8 billion in 2023, then slumped by 56.66% to $5.6 billion in 2024, then declined by 5.36% to $5.3 billion in 2025, then jumped by 78.64% to $9.4 billion in 2026.
• Business Quant data shows ABBV's Cash & Current Investments at $9.4 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.7 billion in Q3 2025.